Integrated pan-cancer analysis and experimental verification of the roles of tropomyosin 4 in gastric cancer
Frontiers in Immunology · 9 authors, 2 centres
AI SUMMARY
FIDELITY 100%
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The central result is that TPM4 expression is associated with diagnosis, prognosis, immune infiltration, and drug sensitivity across multiple cancers, and experimental assays show TPM4 promotes gastric cancer cell migration and invasion.
Full summary
904 CHARS
This study performed a comprehensive pan-cancer analysis of TPM4 using data from multiple public databases (TCGA, GTEx, etc.) to examine its expression, genetic/epigenetic alterations, and associations with immune infiltration and drug sensitivity. In gastric cancer (GC), a ceRNA regulatory network involving lncRNAs, miRNAs, and TPM4 was constructed. Experimental validation using wound healing and Matrigel transwell assays demonstrated that TPM4 knockdown inhibits GC cell migration and invasion. Co-expression analysis linked TPM4 to extracellular matrix (ECM)-related pathways. The study identifies TPM4 as a potential biomarker for diagnosis, prognosis, immunotherapy, and chemotherapy sensitivity (e.g., docetaxel, 5-fluorouracil) in pan-cancer and GC contexts. Limitations include the need for further clinical validation and in vivo experiments to confirm the proposed ECM remodeling mechanism.
